Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 6/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 2/20 | 0.37 |
| ▸ | CASP1 | P29466 | 2/20 | 0.37 |
| ▸ | CASP7 | P55210 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3339408 | 0.82 | MAPK14 (0.40) | GAAABL1KDM4EALDH1A1HPGD | |
| SCHEMBL3017649 | 0.80 | MAPK1 (0.39) | GAAABL1KDM4EALDH1A1HPGD | |
| SCHEMBL3035325 | 0.78 | CYP1A2 (0.40) | GAAABL1KDM4EALDH1A1HPGD | |
| SCHEMBL3029318 | 0.78 | NGFR (0.42) | KDM4EALDH1A1HPGDALOX15MAPK14 | |
| SCHEMBL3031984 | 0.78 | CYP1A2 (0.40) | GAAKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL3024994 | 0.77 | GAA (0.41) | GAAABL1ALDH1A1MAPTALOX15 | |
| SCHEMBL3027631 | 0.75 | GAA (0.41) | GAAABL1KDM4EALDH1A1HPGD | |
| SCHEMBL20568522 | 0.74 | TDP1 (0.38) | GAAKDM4EALDH1A1MAPTMAPK14 | |
| SCHEMBL3023847 | 0.74 | CYP4A11 (0.40) | KDM4EALDH1A1HPGDHSD17B10MAPK14 | |
| SCHEMBL15100750 | 0.72 | TSHR (0.49) | GAAABL1KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11413272-B2 | Inhibitors of metallo-beta-lactamases | OXFORD UNIVERSITY INNOVATION LIMITED | 2022-08-16 | — | — | US | disclosed |
| EP-3630728-B1 | INHIBITORS OF METALLO-BETA-LACTAMASES | UNIV OXFORD INNOVATION LTD (GB) | 2022-07-27 | — | — | EP | disclosed |
| US-20210137884-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| US-20210137884-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| EP-3630728-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | Oxford University Innovation Limited (GB) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018215799-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11413272-B2 | Inhibitors of metallo-beta-lactamases | MGAM, GAA, ALPI | GAA 2/4885ABL1 196/4885KDM4E 2289/4885 |
| US-20210137884-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | MGAM, GAA, ALPI | GAA 2/4885ABL1 196/4885KDM4E 2289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.